Hormonal Contraception and HIV Risk: Understanding the ECHO trial

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.

Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.

The webinar featured:

Beth Schlachter, Executive Director, FP2020
Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
Tamar Abrams, Communications Director, FP2020

You may view the webinar here.

HIV Vaccine Research and Development Pipeline: 2019 Supplement

A slide deck overview of what’s happening in HIV vaccine research now.

Oral PrEP Enrollment Snapshot

For trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot. This PowerPoint deck illustrates major findings from the tracker with heat maps showing where people are initiating PrEP, updates against targets and more. A PDF version is also available.

From Research to Roll Out: Comparing oral PrEP to the dapivirine ring

These slides provide an overview of the process that takes an HIV prevention product from the final phases of research into the real world where it’s broadly available. Also included is a comparison of findings from research on the dapivirine ring and oral PrEP at key points along the process.

A PDF version is also available.

PrEP 101 Presentation from US Women & PrEP Working Group

Created by the US Women and PrEP Working Group, this PowerPoint is intended to help make quality, basic presentations on PrEP to community members.

Harnessing Antibodies for HIV Prevention and Treatment

EATG 2015 Webinar 1: An update on PrEP in Europe

This series of three webinars, hosted jointly by EATG and AVAC, was designed to prepare and update EATG members for a special meeting on new developments in prevention January 2016 in Brussels. The first webinar addressed the latest updates on PrEP in Europe. Speakers: Dr Valentina Cambiano of University College London, Daniela Rojas Castro of AIDES and Dr Anastasia Pharris of the European Centre for Disease Prevention and Control (ECDC).

Post IAS 2015 Webinar: What was presented and what it means on the road to Durban 2016

Advocates and researchers discussed data presented at IAS 2015, its implications and what’s next on the road to Durban 2016!

Transgender Women and PrEP: What’s the latest?

The US Women and PrEP Working Group and partners had a first-hand look at PrEP and transgender women — through the eyes of women prescribing it, using it, choosing not to use it, advocates calling for more research on it and policy-makers charged with integrating it into the national HIV response.

You can click here to view the video.

Slides are also available here.

Breaking Regulatory Barriers for Greater Female Condom Access

A variety of safe and effective female condoms currently exist. However, regulatory hurdles limit new products from entering consumer markets. With the pipeline of new receptive-partner initiated condoms growing, advocates must understand how regulatory issues determine product introduction and approval in their country.

Receptive partner-initiated condoms in development
Link between regulatory environment and female condom access
Current regulatory issues and obstacles
Unique advocacy opportunity to break barriers to existing female condoms and pave the way for emerging internal condoms

You can watch the webinar here.

Stay up-to-date!